BioSpace

Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Capital Markets.

By BioSpace

1 min read
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights